Survival Benefits of Abiraterone Acetate in Patient with Prostate Cancer

OpusPoint Partners leads the way for better, healthier and stronger future for mankind. They are willing to invest resources such as time, money and expertise in helping advanced life sciences and biotechnology. The company believes that they can largely improve the quality of the life science and healthcare industry with the right kind of support. To realize this dream, Dr. Lindsay Rosenwald has established Cougar Biotechnology Inc. which specializes in experimental cancer drugs.
 
The Abiraterone Acetate drug helps extend prostate cancer patients live nearly 4 months longer compared with patients treated with placebo. New research data shows that Abiraterone may become a new oncology compound that could change clinical practice and promote survival benefits in patient with prostate cancer.The Phase 3 trial results may change the lives of men with advanced prostate cancer, since they had very poor diagnosis and almost no available treatment; especially the tumor has progressed after radio- or chemotherapy. The data of the trial has been presented at the European Society for Medical Oncology (ESMO) congress and was found to be very promising. In line with this Dr. Lindsay Rosenwald has struck a billion dollar deal with Johnson&Johnson for Cougar Biotech Labs.
 
Cougar Biotech, a company which was previously funded by Dr. Lindsay Rosenwald’s investment bank is now J&J’s subsidiary, operating in conjunction with Ortho Biotech Oncology Research & Development – a J&J affiliate group. Johnson & Johnson has secured a patent access for Abiraterone and has plans to file sales applications in the United States and Europe.